|Day Low/High||64.38 / 65.25|
|52 Wk Low/High||60.32 / 79.61|
Gilead Sciences, Inc. (NASDAQ: GILD) today announced 48-week results from a Phase 2/3 study (Study GS-US-380-1474) evaluating the efficacy and safety of Biktarvy ® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, BIC/FTC/TAF),...
Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from the DISCOVER trial, a two-year Phase 3 randomized, controlled, double-blind study evaluating the safety and efficacy of the investigational use of once-daily Descovy ® (emtricitabine 200 mg...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Alessandro Riva, MD, Executive Vice President, Oncology Therapeutics, has decided to leave the company to pursue another opportunity.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Robin L.
Gilead Sciences, Inc. (NASDAQ: GILD) today announced it is providing $17.
The RMPIA rose 10.5% during the first half of the current quarter.
YESCARTA is a chimeric antigen receptor T (CAR T) cell therapy that is custom-made for each patient from his or her own T cells.
I still believe it will be a big year for buyouts across the biotech industry.
Gilead Sciences says Selonsertib, a new drug for treating NASH, a type of liver disease, failed Phase 3 trials.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once-daily, oral inhibitor of apoptosis...
It's behavioral finance at its finest, and makes for a fascinating debate.
The biotech company reports downside bottom-line results, though it beats on revenue.
Medicine is a slow business and I view Gilead Sciences as a hold for now.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared an increase of 11% in the company's quarterly cash dividend, beginning in the first quarter of 2019.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2018.
Seagate, Hartford Financial and Gilead are set to report after the bell Monday.
And why maintaining a small position in defense stocks is important.
U.S. stock futures rise modestly as investors focus on stronger-than-expected jobs and manufacturing data from the United States last week; Google parent Alphabet reports earnings Monday after the closing bell; Donald Trump says there's a 'good chance' of a trade deal with China; the New England Patriots win their sixth Super Bowl title.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2018 financial results will be released on Monday, February 4, after the market closes.
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Epclusa ® (sofosbuvir 400mg/velpatasvir 100mg), a once-daily treatment for adults with chronic hepatitis C virus (HCV) infection...
Gilead Sciences, Inc. (NASDAQ: GILD) and Yuhan Corporation (000100.
And it is happening not a moment too soon.
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that members of the executive management team will participate in a fireside chat at the 37 th Annual J.
-- Agenus Webcast and Conference Call Scheduled for Today at 8:30a.m.ET --
Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc.
Gilead Sciences, Inc. (NASDAQ: GILD) and Scholar Rock Holding Corporation (NASDAQ: SRRK) announced today that the companies have entered into a strategic collaboration to discover and develop highly specific inhibitors of transforming growth factor beta...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.